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Abstract 
Background. Mass drug administration (MDA) is the simultaneous treatment of a defined 
population without diagnostic testing, irrespective of the presence of symptoms. MDA has 
been suggested as a malaria elimination strategy since today’s diagnostic tools are 
insufficiently sensitive to detect the low-density, asymptomatic infections thought to fuel 
remaining malaria transmission in low-endemic settings. A cluster-randomized controlled trial 
(CRCT) assessing MDA on Zanzibar was initiated in April 2016. This report investigates the 
impact MDA had on malaria transmission during 16 months follow-up. 
Methods. Eight areas received two rounds of MDA including dihydroartemisinin-piperaquine 
+ single low dose primaquine (0.25 mg/kg) and were compared to eight similar control areas. 
Data on recorded clinical malaria cases detected at health facilities during the follow-up 
period was collected through Zanzibar’s malaria surveillance-system. Cumulative incidence 
and crude risk ratios were used to describe observed trends in malaria transmission. 
Results. During 16 months follow-up MDA fails to achieve a statistically significant lower 
risk of malaria in the intervention arm compared to the control arm; RR=0.85 (95% CI 0.69-
1.03; P=0.10). No risk reduction was observed during the high transmission season 
immediately after MDA; RR=1.16 (95% CI 0.76-1.75; P=0.49). During the following year’s 
(2017) high transmission season the RR was 0.68 (95% CI 0.52-0.88; P=0.004). 
Discussion. Previous studies have concluded that MDA has a rapid effect on malaria 
transmission and that the difficulty is to maintain this effect. No such direct effect could be 
observed in this report. The reason for the observed reduced malaria risk during the high 
transmission season of 2017, one year after MDA was conducted, is unclear. Further analyses 
are needed to confirm the effectiveness MDA had on transmission. 
Keywords. Malaria, mass drug administration, MDA, elimination, Primaquine 
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1 Introduction 
1.1 Malaria in a global perspective  
Malaria, a parasitic disease transmitted through the bites of female Anopheles mosquitoes, is 
a curable and preventable disease. Despite that 212 million people worldwide where infected 
in 2015 according to WHO and 429 000 died due to malaria-related complications the same 
year (1). Children under the age of 5 account for 70 % of these deaths. The parasite 
Plasmodium falciparum cause 99% of global malaria deaths and is the dominant species on 
the African continent. Claiming 76% of the world’s cases and 75% of all malaria deaths, sub-
Saharan Africa is heavily stricken by its malaria burden. However, four other large WHO-
regions – the Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific 
– also pay a heavy toll. Simply put, half of the world’s population is at risk and young 
children and pregnant women are most vulnerable (1). In 2015 the WHO, together with over 
400 experts, put together the Global Technical Strategy for Malaria 2016-2030 (2). It is a 
strategical plan with guidelines to reduce and eliminate malaria. The goals for 2030 include 
reducing malaria case incidence by at least 90%, reducing malaria mortality rates by at least 
90%, eliminating malaria in at least 35 countries and preventing re-establishment of malaria 
in all countries that are malaria free. These goals are being made possible through studies of 
prevention and treatment of Malaria in the endemic regions and one of these outposts, right in 
the heart of the global malaria fight, is Zanzibar where this study took place. 
1.2 Clinical features of the disease  
The disease is divided into uncomplicated and severe malaria with symptoms spanning from 
none to organ failure (3). Fever is the most common symptom of malaria and malaria is also 
the most common cause of fever in high endemic regions (4). Non-specific symptoms like 
fatigue, headache, myalgia, abdominal discomfort, nausea and vomiting is frequent with 
paroxysms of fever (can also be continuous). A phase of chills and shaking followed by a 
warm phase and sweats make up the febrile episodes. Patients with uncomplicated malaria 
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usually do not develop any severe symptoms other than fever and light anemia. Splenomegaly 
can be seen after a couple of days of infection and hepatomegaly and jaundice is not 
uncommon. If treatment with an effective ACT (artemisinin combination therapy) is initiated 
soon after onset of symptoms the mortality rate of uncomplicated falciparum malaria is low 
(less 0.1%) but if left untreated severe illness can emerge (5). P.falciparum is the most lethal 
of the malaria parasites and causes the majority of severe malaria cases. Traits of severe 
malaria are signs of vital organ dysfunction/failure and acidotic breathing due to metabolic 
acidosis and hyper-parasitaemia (5). Cerebral malaria is a form of severe malaria in which 
cerebral microcirculation is disrupted due to blood-clotting, causing convulsions, lowered 
consciousness and coma (4). Severe anemia, as a result of continuous hemolysis and 
destruction of red blood cells by the parasites and the spleen, is also seen in severe malaria 
patients. Other feared traits are renal failure, metabolic acidosis, pulmonary edema, acute 
respiratory distress syndrome (ARDS) and distributive chock. Due to the severity of these 
symptoms, severe malaria is linked to high mortality (3-5). 
1.3 Biology of the malaria parasite 
Unicellular parasites of the Plasmodium genus are the causative agents of malaria. Five 
Plasmodium species are known to cause illness and infection in humans: P. falciparum, 
P.vivax, P. ovale, P. malariae and P. knowlesi (6). Adult female Anopheles mosquitos carries 
the parasite in its salivary glands. Anopheles gambiae, the most abundant Anopheles species 
in Africa, is antropophilic i.e., prefers human blood (6). During feeding the infectious form of 
the parasite, the sporozoites, are released into the human’s circulation and travel to and 
invades the hepatocytes of the liver. Each sporozoite invades one hepatocyte where they 
replicate to form a hepatic schizont containing many merozoites. When the hepatic schizont 
burst it releases up to 40 000 merozoites. P. vivax and P. ovale can lie dormant as hypnozoites 
in hepatocytes for two weeks up to more than a year (4). The merozoites from the ruptured 
schizont enter the circulation and begin infecting red blood cells. Here they feed of 
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hemoglobin and hide from the immune system. In the red blood cells another asexual 
replication takes place, beginning with the merozoite entering a ring-stage and developing 
into a trophozoite. The erythrocyte matures into a schizont containing 6-30 merozoites. 
Eventually the schizont ruptures and the released merozoites can now attack new 
erythrocytes, creating a chain reaction. These blood stages of the malaria parasite, and the 
toxins and waste products leaked from the ruptured erythrocytes, are what causes illness and 
symptoms. The erythrocytic cycle takes 48 h in P. falciparum, P. vivax and P.ovale, 72 h in P. 
malariae and rapid 24 h in P. knowlesi (4). These cycle-times cause the periodicity of the 
paroxysms of chills and fever observed in malaria patients. The infection is asymptomatic 
until blood parasite concentrations of around 50 parasites/microliter, or 100 million parasites 
in an adult’s circulation, is reached. This results in an incubation period of generally 12-14 
days from the infectious mosquito bite (4). 
The intrahepatic and the intraerythrocytic replication cycle are both asexual. Instead of 
becoming a merozoite, some trophozoites differentiate into sexual male and female 
gametocytes that can be transmitted back to another feeding Anopheles mosquito. The male 
and female gametocytes fuse into a motile ookinete that invade the mosquito’s midgut wall. 
The ookinete grows, forming an oocyst that eventually ruptures releasing many sporozoites 
that makes their way to the mosquito’s salivary glands; thus, the cycle is complete(4, 7). 
1.4 Diagnosis and treatment of malaria 
WHO accentuates that suspected malaria cases should have a parasitologically verified 
diagnosis, either by rapid diagnosis test (RDT) or microscopy, before being provided 
antimalarial treatment. This to prevent overuse and development of drug resistance. Gold 
standard for parasitologically verified diagnosis is light microscopy of a thick blood smear by 
an experienced microscopist. This is not always an available method why RDTs have an 
important place in malaria diagnostics. From a finger prick of blood, the RDT detects 
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parasite-specific antigens or enzymes and can, to some degree, differentiate between species. 
RDT is easy to use, cheap and gives the result in 15-20 min and have been found to be a 
suitable tool at primary health care levels (8). RDTs are an essential tool to diagnose 
symptomatic cases in both low and high endemic areas alike. However, in low transmission 
settings, where asymptomatic, low-density infections are relatively more abundant, the 
limitations in sensitivity reduce the usefulness of RDTs to achieve malaria elimination (9). 
PCR is the optimal tool in terms of sensitivity to detect malaria infection, but the method has 
no clinical applicability in today’s endemic regions. PCR is expensive and demands advanced 
laboratory equipment and highly trained operators. PCR might play a more important role in 
the future when more, previously high endemic areas reach a sustainable level of low 
transmission and ultimate elimination is the goal (9, 10). 
Artemisinin combination therapies (ACTs) are the foundation of modern, highly effective 
antimalarial treatment. According to the WHO’s treatment guidelines, a combination of at 
least two different antimalarials, with different pharmacodynamics and half-lives, should be 
used to rapidly and effectively remove parasites and prevent resistance development. ACT 
consist of a fast acting artemisinin derivate, meant to rapidly decrease blood parasite count, in 
combination with a slowly eliminated partner drug that eliminates remaining parasites and 
provide post-treatment prophylaxis (8). Treatment is given for three days and recommended 
ACTs for uncomplicated P. falciparum malaria are: artemether + lumefantrine, artesunate + 
amodiaquine, artesunate + mefloquine, artesunate + sulfadoxine-pyrimethamine and 
dihydroartemisinin + piperaquine. 
ACTs are highly effective and one of the potential greatest threats to the vision of a malaria 
free world is the development and spread of Artemisinin resistance (11, 12). Resistance 
development to Artemisinin has already emerged in the Greater Mekong subregion of 
Southeast Asia, making this threat a reality. 
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ACTs are not fully effective on malaria gametocytes, the parasite-stage accountable for the 
transmissibility back to mosquitos. The WHO guidelines therefore states: 
“In low-transmission areas, give a single dose of 0.25 mg/kg bw primaquine with ACT to 
patients with P. falciparum malaria (except pregnant women, infants aged < 6 months and 
women breastfeeding infants aged < 6 months) to reduce transmission. Testing for glucose-6-
phosphate dehydrogenase (G6PD) deficiency is not required. Strong recommendation, low-
quality evidence.” (8) 
1.5 Malaria control, elimination and eradication 
Each malaria endemic country must eliminate malaria to reach global malaria eradication. The 
path to malaria elimination starts with the incorporation of a national malaria control 
programme. The definition of malaria control is to decrease the burden of malaria (incidence, 
prevalence, morbidity or mortality) to locally acceptable levels. When the slide positivity rate 
(SPR) or RDT positivity rate is <5% among febrile patients or the incidence is <5/1000 
persons at risk the country has reached a pre-elimination phase. When even further progress 
in malaria control is achieved and the incidence of local malaria is as low as 1/1000 persons at 
risk, the country can enter the elimination phase (13). Malaria control, elimination and 
eradication depend on vector control, rapid diagnosis and treatment and malaria surveillance 
and case management. 
Malaria control programs focus on achieving high population coverage of vector control 
interventions and ensuring easy access to diagnosis and effective treatment to reduce malaria 
incidence and mortality. Vector control aims to limit the mosquitos contact with humans and 
therefore prevent malaria infection and transmission. There are two primary vector control 
tools: insecticide-treated mosquito nets (ITNs) and indoor residual spraying (IRS) with 
insecticides. IRS was the core of the Global Malaria Elimination Programme’s success in the 
1950s and 60s but today’s achievements in malaria control are mostly due to the world-wide 
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deployment of ITN and the long-lasting insecticidal nets (LLINs). WHO recommends that 
100% of the population at risk of malaria sleeps under a LLIN but in 2015, 47% did not (1). 
IRS are effective due to the behavior of the vectors. Most biting occurs indoor during the 
evening and night hours (hence why LLIN are so important) and after the feeding of blood, 
the mosquito resides on the walls and ceilings of the house, digesting their meal (6). IRS 
therefore consists of spraying walls and ceilings with insecticides, killing the vector. 
Rapid diagnosis and treatment is important since uncomplicated infection in a fast pace can 
evolve into severe illness. Sever falciparum malaria is deadly in almost all cases if treatment 
is not provided. The aim is to initiate ACT treatment within 24-48 hours after onset of 
symptoms (8). Fast identification and treatment of cases also limit the onward transmission 
form an individual case. 
Malaria surveillance is essential in a country moving towards elimination. The ability to 
detect each new case and document, track and gather additional information about every new 
case becomes increasingly important as transmission declines (14). Transmission is highly 
heterogeneous in malaria endemic regions, especially in low-transmission settings, and cases 
often stem from small foci of higher transmission. Transmission can also be heterogeneous 
within these foci, and areas with transmission intensity above average are called hotspots. 
Hotspots contain the epidemiological and geographical features required for nourishing 
transmission (15). The ability to detect and map these foci or hotspots, which may sustain 
transmission, is an important task of malaria surveillance systems, making it possible to 
mobilize targeted efforts and interventions. A scale-up of the surveillance systems into a core 
intervention is one of the “three pillars” WHO’s Global Technical Strategy for Malaria 2016-
2030 relies on to achieve its goals of 90% reduction in global malaria incidence and mortality 
(2). 
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Passive case detection (PCD) is the cornerstone of malaria surveillance. This is the detection 
of a new cases when they seek medical assistance at health facilities. Active case detection 
(ACD) is the active search and screening for malaria infection in populations and is important 
since not all malaria cases, for example asymptomatic carriers, are detected through PCD. As 
a response to a detected case (either by PCD or ACD) a reactive case detection (RACD) 
strategy can be carried out. RACD means that individuals, surrounding a diagnosed case, are 
screened and treated if found positive (14). 
As transmission declines, and countries move towards elimination, the relative proportion of 
low-density/sub-patient infections increases (16). Subpatient malaria infections are defined as 
parasitaemias detectable by PCR but not by RDT or microscopy. Low-density/sub-patient 
infections (<100 parasites/microliter of blood) are to a wide extent asymptomatic and are 
therefore missed by PCD. They also avoid detection by ACD since ACD depends on RDTs 
for finding infections. With today’s tools, asymptomatic and subpatient infections can 
accumulate into a human parasite reservoir that may maintain malaria transmission through 
gametocyte development. When the aim is elimination, finding these sub-patient parasite 
carriers becomes increasingly important since they have been estimated to fuel 20-50% of 
human-to mosquito transmission in pre-elimination areas (17). To effectively target the sub-
patient parasite reservoir is one of the greatest challenges to achieve malaria elimination. The 
symptomatic and asymptomatic biomass of malaria parasites are higher in hotspots than other 
areas which allows for targeting of the human parasite reservoir. Focusing efforts and 
interventions to hotspots may therefore be an effective way to reduce malaria transmission 
(15). WHO’s Global Technical Strategy also points out that targeting the reservoir is an 
important step in accelerating the pace towards elimination (2). 
The ultimate goal of malaria eradication calls for universal access to these core control and 
elimination tools/strategies in all endemic regions. The endemic regions consist of some of 
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the poorest and most remote corners of the world making this prospect highly dependent on 
substantial investments and global commitment. Due to the Global Fund to Fight AIDS, 
Tuberculosis and Malaria, the President’s Malaria Initiative and many others the global 
funding has increased significantly from US$ 960 million in 2005 to US$ 2.9 billion in 2015 
(18, 19).  
1.6 Targeting the parasite reservoir 
Malaria elimination from previously high endemic areas, containing all the right geographical 
and epidemiological factors to uphold transmission, is no easy task. Despite universal 
coverage of core interventions and a strong health and surveillance systems, low levels of 
transmission linger. PCR has pointed out the large pool of asymptomatic/sub-patient parasite 
carriage that contribute to the remaining transmission in low-transmission settings (20). 
Finding and treating these carriers should be a priority of any elimination strategy. 
There are two major tactics to reach the asymptomatic pool of parasite carriers. Mass 
screening and treatment (MSAT), where you screen a population and treat those found 
positive, is one of them. MSAT’s weakness in malaria elimination is that it depends on highly 
sensitive, in-field available, diagnostic tools. RDT’s sensitivity (approximately 100 
parasites/microliter of blood) has shown to be insufficient to find the asymptomatic/sub-
patent parasite carriers, rendering MSAT not a viable option to achieve malaria elimination. 
That is until in-field suitable diagnostic tools with high enough sensitivity, comparable to 
PCR, become available (21, 22). 
Mass drug administration (MDA) is one way around the issue of finding the sub-patient 
infections. MDA is mass treatment of all individuals of a population at approximately the 
same time, regardless of the presence of symptoms and without prior diagnostic testing (23). 
MDA with antimalarials enables the targeting of the sub-patent human parasite reservoir and 
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may interrupt transmission in low transmission settings and play an important role in 
elimination.  
1.7 Mass drug administration (MDA) for malaria 
The high efficacy of ACTs, the transmission blocking properties of primaquine and the 
presence of sub-patent infections potentially fueling transmission has renewed the interest in 
MDA for malaria elimination. MDA was used as early as 1910 against Malaria (24). It was 
used more extensively during the 1950s during the eradication programme, to wide extents in 
China and Russia and in research across several different endemic settings with mixed 
success (25). Because of the generally low quality of available data, a lot is still unknown 
about the specifics and actual effectiveness of MDA. The optimal drug combination, timing 
(when MDA is administered in relation to the malaria season), number of rounds and for how 
long MDA should be repeated are key features that need answers (26). Reviews on the subject 
(27, 28) has concluded that MDA has to be further examined and more high-quality cluster 
randomized controlled trials are needed. Available data show that MDA has been most 
successful in low transmission settings aiming for elimination but most studies fail to display 
a persistent effect lasting longer than six months. Isolated small islands and remote highlands 
have been most successful. Important aspects of successful MDA are: Community 
participation and coverage >80%, making the delivery system of MDA a very important 
factor. Furthermore, high coverage of vector control interventions has been part of most 
successful MDA regimens. The use of Primaquine (transmission blocking properties) is 
crucial to effectively target all stages of the malaria parasite’s life cycle. Timing of MDA is 
also of great significance and varies between settings; in areas with seasonal transmission 
MDA has the greatest chance to interrupt transmission at the lowest point of transmission 
(25). Since malaria incidence correlate with rainfall, this is usually during the dry season just 
before the onset of the wet season. Since high coverage is key, timing of MDA also has to be 
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planned around patterns of population movement (for example to earn alternative income 
during parts of the year) (25). The time of the year when the population is most stationary 
gives the best opportunity to achieve high coverage. 
Brady et al. (2017) (29) address some of the key features of successful MDA in low-
transmission settings using mathematical consensus modelling. They conclude that MDA has 
a suppressing effect on transmission more long-lasting than the prophylactic effect of the 
given treatment. The relative effect on transmission is more pronounced and long-lasting the 
lower the starting level of transmission is; MDA should be done at the lowest point of 
transmission during the year. The effect of MDA is only short-termed and sustained long-term 
effect depends on strengthened vector control and/or other interventions; otherwise MDA has 
to be repeated frequently. Simulated MDA effectiveness greatly depends on total yearly 
population coverage and if that is achieved by one or multiple rounds of MDA is less 
important. MDA conducted during 2 years was more effective than during 1 year. 
In an era of emerging artemisinin resistance, MDA is a controversial method. A restrictive 
view on the use of ACTs, to only parasitically verified malaria cases, is adopted in WHO’s 
treatment guidelines to prevent artemisinin resistance. Despite that, part of the reborn interest 
in MDA arise due to the emergence of artemisinin resistance in the in the Greater Mekong 
subregion of south east Asia. The fear of artemisinin losing its efficacy is wide-spread among 
the malaria fighting communities and the spread of resistant strains to Africa, and the rest of 
the endemic regions, would be catastrophic. Therefore, the gathering of WHO’s Evidence 
Review Group in 2015 (23) resulted in MDA being recommended as a “fighting fire with 
fire” tactic to contain/eradicate resistant strains in the Greater Mekong subregion. They also 
recommend MDA in low-transmission settings aiming for elimination, since these conditions 
allow MDA to interrupt remaining low-level transmission to the point where it can’t recover. 
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MDA is also recommended to radically lower malaria mortality and morbidity in epidemic 
scenarios and other emergency situations, when the health system is overpowered (23).  
1.7.1 Choice of drugs to be used in MDA 
Each round of MDA consists of a full treatment and therefore involves multiple doses over a 
number of consecutive days. Completion of all doses is essential for MDA (23) and in a MDA 
study from Gambia (30) the most common reason for not completing the cure was fear of 
side-effects. The drug combination must therefore be safe and accepted by the receiving 
communities to achieve high enough coverage and compliance. An easy drug regimen is also 
preferred to achieve high compliance of all doses. 
The optimal drug combination of MDA has yet to be defined but should comprise of an ACT 
in combination with a potent gametocytocidal drug to effectively remove gametocytes and 
therefore suppress transmission (23). Primaquine is the only gametocytocidal drug 
commercially available. The downside of using Primaquine is the risk of adverse side effects, 
including toxic hemolysis in glucose-6-phosphatese (G6PD) deficient patient. G6PD 
deficiency is the result of a genetic mutation that, due to natural selection, is more abundant in 
malaria stricken parts of the world as it gives about 50% protection against severe malaria 
(31). As stated before, the WHO recommends the addition of SLD Primaquine (0.25 mg/kg) 
for the treatment of uncomplicated P.falciparum malaria in low-transmission settings. The 
WHO Evidence Review Group also conclude that SLD primaquine (0.25 mg/kg) is 
recommended for MDA regimens (23). The risk and degree of hemolysis in G6PD deficient 
patient are dose and exposure duration dependent and the use of SLD primaquine is therefor, 
without prior testing, considered safe in G6PD abundant populations (8, 32). 
Proposed regimens for MDA is dihydroartemisinin-piperaquine + SLD Primaquine (0.25 
mg/kg). The ACT, Dihydroartemisinin-piperaquine (DHAp), is taken once a day for 3 days. 
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MDA at large scales drastically increase the drug pressure (the circulating amount of the 
drug) which could be argued gives a natural selection of resistant strains and predispose 
spread since it wipes out rivaling, sensitive strains (24). To minimize this risk, the drug 
combination of MDA should not be the same as the first line treatment for individual cases 
and the addition of a transmission blocking drug, like primaquine, is key to limit the spread of 
resistant parasites (23). However, if MDA fails to eliminate malaria from the targeted areas, it 
may drive resistance development (8). 
1.7.2 Delivery strategy of MDA 
Aside from the safety profile of the drug, the delivery system of the drug is equally important 
to achieve >80% coverage and compliance of MDA. Before MDA is engaged, the 
communities have to be involved and educated about why and how MDA will be conducted. 
Information about the drugs and risk of side-effects must be included. This to build a general 
foundation of trust and understanding. Involvement of elders and local leaders (social, 
political, religious etc.), who can motivate their community, can further enhance acceptance 
and participation (23, 25).  
The area targeted for MDA should be divided into smaller areas, each for which a team of 
local health workers/volunteers are responsible. The use of local volunteers will increase 
community involvement and the delivery teams should administer the drugs using a house-to-
house approach. Directly observed therapy (DOT) of all doses is central to achieve 
compliance goals and the small but many delivery teams will make this possible on large 
scales. Staff administering the drugs should be educated to recognize adverse events of the 
drugs and health care workers at health facilities should also be trained to handle these events 
(like hemolysis) (23, 25). The population must know that they should seek medical attention 
and can get help at health facilities if adverse events occur. 
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1.8 MDA on Zanzibar 
Zanzibar (population 1.3 million), a semi-autonomous archipelago outside the coast of 
Tanzania, a previously high endemic setting of malaria in sub-Saharan Africa, has now 
reached pre-elimination status. Between 2003 and 2015 they achieved a 96% reduction in in 
RDT/microscopy verified P. falciparum prevalence from 10.3% (95% CI 9.3 – 11.4) to 0.43% 
(95% CI 0.23-0.73). The all-cause mortality in young children (<5 years) declined by 64% 
(Bjorkman et al, unpublished). This transformation was made possible in only 15 years due to 
the nation-wide deployment of core malaria interventions; ACT in 2003, RDT in 2005 and 
LLIN and IRS in 2006. Malaria incidence dropped massively after the implementation of 
these interventions and hopes of elimination arose. However, in 2007 the decline in 
transmission leveled out and a remaining low-level transmission has been stable since. 
Transmission is now also more seasonal and heterogenous with remaining foci of 
transmission. PCR has revealed an almost 4 times higher parasite prevalence than RDT, 
indicating the presence of a large sub-patent/asymptomatic parasite reservoir. 
In 2013, the Zanzibar Ministry of Health officially changed their target from malaria control 
to elimination. Zanzibar Malaria Elimination Programme (ZAMEP) has two malaria 
surveillance systems; Malaria Early Epidemic Detection System (MEEDS) and the Malaria 
Case Notification (MCN) system. MEEDS is a PCD system to which health facilities report 
malaria cases once weekly. MCN is both a PCD and ACD system where every new case 
detected is registered in real time and is later followed up by a District Malaria Surveillance 
Officer (DMSO) at the house-hold level. Individuals in the index case’s household is tested 
by RDT and, if found positive, treated. The DMSO also collect additional information about 
those found positive and the information is documented in MCN; information such as recent 
travel and use of LLIN. If household members are tested positive by RDT, a wider screening 
of direct neighbors are conducted. 
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Zanzibar was among the first in sub-Saharan Africa to introduce ACT (artesunate and 
amodiaquine) as first-line treatment and other interventions on a wide scale (33) and the goal 
is to provide proof of the feasibility of malaria elimination from a previously high endemic 
area. A MSAT study in 2015 demonstrated that the sensitivity of RDT was too low to find the 
low density, asymptomatic infections thought to play a vital role in maintaining transmission 
(21). As a result, a study to evaluate MDA’s potential in achieving elimination on Zanzibar 
was initiated in 2016. Zanzibar is a good location to assess MDA. It’s an island and pre-
elimination setting, the remaining transmission is highly seasonal and hotspots of 
transmission has been identified through the malaria surveillance systems already in place. 
MDA was used in 2013 as an outbreak response in four hotspot Shehias (smallest 
administrative unit) (34). The outbreak was noticed through MCN when all four Shehias 
reported over the alert threshold of 5 cases/week, only 2-6 weeks after they received MSAT. 
One round of MDA was distributed via house-to-house visits and was well accepted; 97% 
coverage and 90% compliance were reported. MDA’s effect on malaria transmission was not 
assessed. 
The malaria transmission of Zanzibar is low and highly seasonal and most cases are recorded 
during May-September. This period is referred to as the high transmission season occurs 
shortly after the start of the wet season, ranging from April to June. To assess the 
effectiveness of MDA in reducing the annual peak in transmission, a cluster-randomized 
controlled trial (CRCT) with one intervention arm (two rounds of MDA) and one control arm 
(no MDA) was initiated in April 2016. This report presents the trends in malaria transmission 
during the 16 months follow-up after the administration of MDA. 
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2 Study aim(s) and objective(s) 
2.1 Aim 
To investigate the impact of two rounds of dihydroartemisinin-piperaquine (DHAp) + single 
low dose (SLD) primaquine Mass Drug Administration (MDA) on seasonal malaria 
transmission in areas (Shehias) considered hotspots in Unguja Island, Zanzibar. 
2.2 Objectives 
2.2.1 Primary objective 
To compare the cumulative malaria incidence in the control (no MDA) and intervention 
(MDA) arms during the study period May 2016-September 2017. 
2.2.2 Secondary objective 
To compare malaria cumulative incidence in the control and intervention arms during the high 
transmission seasons in May-September 2015, 2016, 2017, i.e. prior to and after the MDA. 
3 Method 
3.1 Study design 
This is a follow-up on a CRCT with two arms: an intervention arm with two rounds of MDA, 
and a control arm with no MDA. Each arm contained eight clusters (Shehias). The study was 
initiated on 30th April 2016. Two rounds of MDA with DHAp (D-ARTEPP, Guilin 
Pharmaceutical (Shanghai) Co., Ltd., China) and SLD (0.25mg/kg) primaquine (Primaquine, 
Remedica Ltd.,Cyprus ) was administered approximately four weeks apart (day 0 and 28), at 
the anticipated lowest point of malaria transmission before the onset of the annual high 
transmission season occurring after the start of the rainy season (April-June). A total of 22 
teams, consisting of two health care workers and one community guide, delivered MDA 
during house-to-house visits and the coverage (proportion of the population that received 
treatment) for each round was determined. SLD primaquine and the first dose of DHAp was 
taken under direct observation (DOT) in individuals that were present and agreed to 
treatment. The two remaining doses of DHAp was left with clear instructions. Post MDA 
surveys were conducted seven days after each round of MDA in a subset of the MDA 
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households in order to estimate the self-reported compliance to the three-day DHAp treatment 
regimen. Safety of this combination of MDA was also evaluated by the same post MDA 
surveys using a structured questionnaire covering adverse events. Passive monitoring of 
severe adverse events, such as haemolysis, took place at the health facilities connected to the 
study areas. Before MDA was implemented, the staff of the health facilities received training 
and education about recognizing and handling adverse events of the included drugs, risk of 
acute haemolysis being the most important. To boost understanding, acceptance and 
participation, the communities were informed about the purpose and the procedure of the 
study before the study was initiated and local village leaders were also involved. 
3.1.1 Study sites 
The majority of Zanzibar’s symptomatic malaria cases are recorded on the island Unguja 
following the main rains which occur between April-June. A total of 16 clusters in Central, 
South, and West districts, Unguja Island, Zanzibar were randomly selected then randomized; 
8 for MDA and 8 for control. Each cluster consisted of a hotspot Shehia, defined as a Shehia 
with an annual malaria incidence of >8/1000 (i.e. >0.8%) calculated as the number of 
confirmed malaria infections notified at health facilities and during active case detection 
during January-December 2015/projected Shehia population for 2015. The allocation of 
Shehias within the trial arms was conducted using computerized block randomization based 
on Shehia population size. The districts were originally chosen since they have the biggest 
concentration of hotspot Shehias/district. 
3.1.2 Sample size of original study 
To detect a 50% reduction in annual incidence (from baseline 12/1000 in included Shehias to 
6/1000 in the intervention arm) with 80 % power and a mean Shehia population of 1450, eight 
clusters in each arm were required. This resulted in roughly 12,000 individuals in each arm 
giving a total sample size of around 24,000. 
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3.1.3 MDA implementation 
According to the MDA implementation report, the coverage of the first round of MDA was: 
91% received DHAp, 87% received SLD Primaquine and 67% took the first dose as DOT. 
The coverage of the second round of MDA was: 88% received DHAp, 81% received SLD 
Primaquine and 48% took the first dose as DOT. A post MDA survey in a subset of the 
households of the MDA Shehias assessed the compliance to the full treatment to 84% and 
96% in the first and second round respectively. 
3.2 Study procedure and data collection for this report (16 months follow-up) 
In November 2016, six months after the second round of MDA, the short-term impact of 
MDA was evaluated by comparing crude cumulative incidence of malaria in the MDA and 
control Shehias during May-November (the CRCT’s primary objective). The crude malaria 
cumulative incidence was calculated as: the number of verified malaria cases from the 
Shehias of the study arm divided by the estimated population size of the study arm. The 
malaria cases were detected by PCD at health facilities and monitored through MCN. MCN 
contains information about in which Shehia a malaria positive individual lives. MCN 
therefore allows tracking of malaria cases from the intervention and control arm irrespectively 
of where on Zanzibar the case is confirmed. The populations of the two study arms were 
estimated using a population enumeration census from 2012 with an annual growth rate of 
2.8%. This study assessed the long-term impact of MDA by comparing cumulative incidence 
in the control and MDA Shehias six and 12 months after MDA and during the entire study 
period May 2016-September 2017 (16 months). Comparison of cumulative incidence in MDA 
and Control Shehias during high transmission seasons May-Sep 2015, 2016 and 2017 was 
also conducted. 
Data of malaria cases among the residents of the study Shehias, reported at health facilities 
across Zanzibar, was downloaded from the MCN database for the period May 2016-Sep 2017. 
Data from period May-Sep 2015 was also obtained for the secondary objective. Data was 
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checked for inconsistencies and errors; doublets of the same malaria case (malaria case ID), 
diagnosis date, Shehia info and travel history info. Through this MCN data analyses regarding 
MDA´s long-term effectiveness in reducing malaria transmission in the study Shehias were 
done. Data of all malaria cases reported at health facilities on the whole island Unguja was 
also downloaded from the MEEDS database for the time-period week 1 2014 to week 40 
2017. This data was obtained to cross-check the MCN data and calculate RDT testing and 
positivity rates at health facilities. Testing rate for each year was calculated as the number of 
patients tested with RDT divided by the total number of patients seeking help at health 
facilities. Positivity rate for each year was calculated as the number of patients testing positive 
for malaria by RDT divided by the total number that were tested. Furthermore, available 
rainfall data from 2014-2017 was also acquired from Tanzania Meteorological Agency.  
3.3 Statistical analysis 
The MCN data was cleaned and processed using Excel 2016. Further statistical analyzes were 
conducted in IBM SPSS Statistics 25. Descriptive statistics was used to describe the study 
populations and the study outcomes. The cumulative incidences of malaria in MDA and 
control Shehias during a specific time period were compared by calculating the crude risk 
ratio (RR) for malaria between MDA and control Shehias for that specific time period. 
Kaplan-Meier hazard plots of cumulative malaria incidence in MDA vs control areas were 
produced to visualize the primary objective’s result. The RRs for the different time periods 
was produced by crosstabulation in SPSS and the Kaplan-Meier hazard plots were produced 
by Kaplan-Meier survival analysis in SPSS. The statistical significance threshold was set at 
0.05. 
A significant portion of Zanzibar’s malaria cases are thought to be imported. To assess 
MDA’s effect on local transmission (i.e., malaria acquired inside the study Shehias), RR 
analyses were repeated after exclusion of all potentially imported malaria cases (cases with 
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history of travel overnight outside of Zanzibar and/or outside Shehia within 30 days of 
malaria diagnosis). 
3.4 Ethical considerations 
This is a follow-up on a study that was conducted with the ethical approval from Zanzibar 
Medical Research Ethical Committee (ZAMREC). All participants were also informed of the 
purpose and benefits of the study, as well as potential risks and side-effects of MDA. Written 
consent of participation in the study were obtained from heads of households. It was 
emphasized that participation was non-compulsory. All study activities were conducted in 
conformity with the local culture and customs. 
MDA is a controversial method. The ethics of exposing whole populations of the potential 
side effects of drugs is debatable. Primaquine is known for serious side effects like toxic 
hemolysis in G6PD-deficient patients. Despite this, WHO recommends the addition of SLD 
primaquine to all P. falciparum cases, in low-transmission settings, without screening for 
deficiency. The WHO Evidence Review Group has also suggested the use of SLD primaquine 
in MDA regimens (23). The risk and degree of hemolysis in G6PD deficient patient are dose 
and exposure duration dependent and the use of SLD primaquine (0.25 mg/kg) is therefor 
considered safe without prior testing in G6PD abundant populations (8, 32). 
WHO recommends the verification of a parasitic infection, before malaria treatment is 
administered, to reduce drug overuse as a factor contributing to drug resistance development. 
MDA oppose that recommendation and might be a source of progressing resistance 
development. To minimize this risk, the drug combination of MDA should not be the same as 
the first line treatment for individual cases and the addition of a transmission blocking drug, 
like primaquine, is key to limit the spread of resistant strains (23). However, if MDA fails to 
eliminate malaria from the targeted areas it may drive resistance development (8). 
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4 Results 
4.1 Cumulative malaria incidence after MDA 
MDA was initiated on the 30th April 2016, therefore the follow-up period starts 1 May 2016 
and MCN data was collected up to 31 August 2017; for a total of 16 months follow-up. A 
total of 389 RDT confirmed malaria cases from the study Shehias were detected by PCD at 
health facilities, and were reported in MCN during this time period. 173 cases were from the 
intervention arm (MDA) and 216 were from the control arm. Characteristics of the recorded 
cases can be seen in table 1. Figure 1 displays the weekly number of cases reported in the two 
study arms respectively during the study period. Figure 1 also displays when the two rounds 
of MDA were administered and the different follow-up periods of this report. 
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Tabell 1. Characteristics of clinical malaria cases (detected at health facilities and reported through MCN) in the 
two study arms during the study period May 2016-Sep 2017. 
 
VARIABLE 
 
MDA SHEHIAS 
 
CONTROL SHEHIAS 
NUMBER OF MALARIA CASES 173 216 
MEDIAN AGE (YEARS) 15 19.5 
AGE GROUPS (YEARS)   
<5 (%) 18.5 8.8 
5-9 (%) 7.5 10.7 
10-14 (%) 12.1 10.2 
15-19 (%) 12.1 13.4 
20-29 (%) 16.8 19.4 
30-39 (%) 5.8 7.9 
40-49 (%) 4.6 6.0 
50-59 (%) 1.2 5.6 
60- (%) 2.3 4.2 
MISSING INFO (%) 19.1 13.9 
SEX   
FEMALE (%) 26.0 31.5 
MALE (%) 44.5 50.9 
MISSING INFO (%) 29.5 17.6 
SLEPT UNDER LLIN NIGHT 
BEFORE TESTING POSITIVE 
  
YES (%) 37.6 44.4 
NO (%) 23.1 24.5 
MISSING INFO (%) 39.3 31.0 
HISTORY OF TRAVEL 
OVERNIGHT WITHIN 30 DAYS 
  
YES (%) 28.3 22.7 
NO (%) 71.7 77.3 
Abbreviations: MDA, mass drug administration; MCN, malaria case notification; LLIN, long lasting 
insecticidal net. 
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Figure 1. Weekly clinical malaria cases (detected at health facilities and reported through MCN) among the 
residents of the MDA and control Shehias during the time period May 2016-Sep 2017 (16 months follow-up). Black 
arrows mark the administration of the two rounds of MDA (week 18 and 22), orange arrows mark the high transmission 
season of 2016 and 2017 (week 18-36). Green arrow marks the 16 month follow-up, yellow arrow marks the 12 month 
follow-up and purple arrow marks the 6 month follow-up.  
 
The 2016 population sizes of the study arms were estimated from the 2012 population 
enumeration survey to be 11 576 in MDA Shehias and 12 239 in control Shehias. The 173 
recorded malaria cases in the intervention arm is therefore equal to a cumulative incidence of 
1.49% during 16 months follow-up which translates into 11 cases/1000 person-years. The 216 
cases from the control arm during the same time period is equal to a cumulative incidence of 
1.76% or 13 cases/1000 person-years. Cumulative incidence for 6 and 12 months post MDA 
was also analyzed and the number of cases, population sizes and cumulative incidences 
during different time-periods can be found in table 2. A visualization of the cumulative 
incidence of malaria in the study arms during the 16 months following administration of 
MDA can be seen in the Kaplan-Meier hazard plot displayed in figure 2 A). 
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The cumulative incidence of malaria in MDA Shehias was divided by the cumulative 
incidence in control Shehias to generate a crude risk ratio (RR) of malaria between MDA and 
control Shehias for each specific time period. The RR of malaria between MDA and control 
Shehias was 1.27 (0.87-1.85; P=0.21) after 6 months, 1.17 (95% CI 0.86-1.61; P=0.32) after 
12 months, and 0.85 (95% CI 0.69-1.03; P=0.10) after 16 months post MDA (i.e., equal to a 
non-significant 15% reduction in risk of malaria in the MDA arm compared to the control 
arm. RRs during different time-periods can be seen in table 2. 
A significant portion of Zanzibar’s malaria cases are thought to be imported. The RR between 
MDA and control Shehias for locally acquired malaria (inside the study Shehias) was 1.32 
(95% CI 0.80-2.17; P=0.27) after 6 months, 1.08 (0.71-1.65; P=0.71) after 12 months and 
0.79 (95% CI 0.62-0.99; P=0.04) after 16 months post MDA. Cumulative incidences of 
locally acquired malaria during different time-periods and the matching RRs can be found in 
table 2. Figure 2 B) displays a Kaplan-Meier hazard plot of cumulative incidence of locally 
acquired malaria during 16 months post MDA. Figure 2 B) (local transmission) shows the 
same trends as figure 2 A) (all cases) with a greater dispersion between the two graphs at the 
end of the study period, representing the 21% lower risk in MDA Shehias compared to control 
during the full 16 months follow-up period (RR=0.79; P=0.04).  
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Table 2. Overview of cumulative incidence of clinical malaria (detected at health facilities and reported through MCN) in the two study arms and crude risk ratios (RR) of clinical 
malaria between the MDA and control arm during 16 months follow-up (May 2016-Sep 2017) and during high transmission season May-Sep 2015, 2016 and 2017. Significant p values are 
marked in bold. 
 
 
TIME PERIOD 
 
 
STUDY ARM 
 
 
MALARIA CASES 
 
POPULATION 
SIZE 
 
CUMULATIVE 
INCIDENCE (%) 
 
 
RISK RATIO (RR) 
95% 
CONFIDENCE 
INTERVAL 
 
SIGNIFICANCE 
6 MONTHS MDA 60 11 576 0.52 1.27 0.87-1.85 P = 0.21 
 Control 50 12 239 0.41 Reference   
12 MONTHS MDA 81 11 576 0.70 1.17 0.86-1.61 P = 0.32 
 Control 73 12 239 0.60 Reference   
16 MONTHS MDA 173 11 576 1.49 0.85 0.69-1.03 P = 0.10 
 Control 216 12 239 1.76 Reference   
6 MONTHS MDA 35 11 576 0.30 1.32 0.80-2.17 P = 0.27 
LOCAL CASES Control 28 12 239 0.23 Reference   
12 MONTHS MDA 44 11 576 0.38 1.08 0.71-1.65 P = 0.71 
LOCAL CASES Control 43 12 239 0.35 Reference   
16 MONTHS MDA 124 11 576 1.07 0.79 0.62-0.99 P = 0.04 
LOCAL CASES Control 167 12 239 1.36 Reference   
HTS 2015 MDA 127 11 260 1.13 1.23 0.96-1.59 P = 0.11 
 Control 109 11 906 0.92 Reference   
HTS 2016 MDA 47 11 576 0.41 1.16 0.76-1.75 P = 0.49 
 Control 43 12 239 0.35 Reference   
HTS 2017 MDA 92 11 900 0.77 0.68 0.52-0.88 P = 0.004 
 Control 143 12 582 1.14 Reference   
HTS 2015 MDA 85 11 260 0.75 1.11 0.82-1.50 P = 0.50 
LOCAL CASES Control 81 11 906 0.68 Reference   
HTS 2016 MDA 33 11 576 0.29 1.40 0.83-2.35 P = 0.21 
LOCAL CASES Control 25 12 239 0.20 Reference   
HTS 2017 MDA 80 11 900 0.67 0.68 0.52-0.90 P = 0.007 
LOCAL CASES Control 124 12 582 0.99 Reference   
Abbreviations: MCN, malaria case notification; HTS, high transmission season; RR, risk ratio. 
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Figure 2. Kalplan-Meier hazard plots of cumulative incidence of clinical malaria in the two study arms during the 
time period May 2016-Sep 2017 (488 days). Panel A) displays all clinical malaria cases detected at health facilities. In 
panel B) all potentially imported malaria cases have been excluded to display only cases infected by local transmission 
inside the study Shehias.   
 
A) 
B) 
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4.2 Cumulative malaria incidence during high transmission season 2015, 2016 and 
2017 
The majority of Zanzibar’s malaria cases occur during the high transmission season ranging 
between May-September. The secondary objective of this report was therefore to investigate 
whether MDA had an impact on seasonal malaria transmission. In 2015, the year before 
MDA, there were 236 cases of malaria from the study Shehias (detected by PCD and reported 
to MCN) during the high transmission season. During the same period in 2016 there were 
only 90 cases and during 2017 there were 235 cases. The distribution of cases between MDA 
and Control Shehias can be seen in table 2. Figure 3 displays the weekly number of cases in 
MDA and Control Shehias respectively during the high transmission season 2015, 2016 and 
2017. There were slightly more cases and higher cumulative incidence in MDA Shehias 
during the high transmission season 2015 and 2016, although the difference was not 
significant. In 2015, the RR of malaria between MDA and Control Shehias during the high 
transmission season was 1.23 (95% CI 0.96-1.59; P=0.11) and in 2016 the RR was 1.16 (95% 
CI 0.76-1.75; P=0.49). During the high transmission season 2017 there were fewer cases and 
lower cumulative incidence in MDA Shehias compared to control and the RR was 0.68 (95% 
CI 0.52-0.88; P=0.004) equal to 32% reduced risk of malaria in MDA Shehias compared to 
control. The cumulative incidences and the RRs for the different time periods can be found in 
table 2. 
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Figure 3. Weekly clinical malaria cases (detected at health facilities and reported through MCN) among the 
residents of the MDA and control Shehias during high transmission season (May-Sep, week 18-36) 2015, 2016 and 2017. 
 
Similar trends apply for local transmission during the studied high transmission seasons. 
There was no significant difference between MDA and control Shehias in 2015 (RR=1.11; 
P=0.50) and 2016 (RR=1.4; P=0.21). During the high transmission season 2017 there was 
32% significantly lower risk of locally acquired malaria in MDA Shehias compared to control 
(RR=0.68; P=0.007). Cumulative incidences and RRs can be found in table 2. 
4.3 Cross-checking and validation of MCN data 
The results of this report are derived from MCN data. As observed previously in the results 
section, there seems to be generally lower incidence of malaria in both MDA and control 
Shehias during high transmission season 2016 (table 2 and figure 4) compared to 2015 and 
2017. Lower incidence was not expected in both study arms post MDA. To cross-check the 
MCN data, it was compared with MEEDS data from the health facilities in the study Shehias. 
The MCN data allows tracking of all residents of the study Shehias that are tested positive for 
malaria, regardless of where on Zanzibar they are tested. The MEEDS data provides 
information about all cases that are tested positive for malaria at the health facilities of the 
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study Shehias; MEEDS data therefore captures some cases that are not residents of the study 
Shehias. Since most of the residents of the study Shehias are assumed to seek medical 
attention at the health facilities in the study Shehias, MCN and MEEDS data should be 
similar. This is the case and can be observed in figure 4. This suggests that the MCN data is 
accurate. 
 
 
Figure 4. Comparison of MCN and MEEDS data from the study Shehias (MDA+control) during high transmission 
season (May-Sep, week 18-36) 2015, 2016 and 2017. MCN data displays the weekly number of clinical malaria cases 
among the residents of the study Shehias (detected at health facilities across Zanzibar). MEEDS data displays the weekly 
number of cases tested positive at the health facilities in the study Shehias.     
 
The generally lower malaria incidence observed in the MCN and MEEDS data from the study 
Shehias during High transmission season 2016 could be a result of reduced RDT testing rate 
at health facilities. To check if this was the case MEEDS data was used since it contains 
information about how many patients that seeks medical help, how many that are tested with 
RDT and how many that are found malaria positive. With this data the RDT testing rate and 
RDT positivity rate of different years was analyzed (see table 3). There was no drop in RDT 
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testing rate in the study Shehias or on Unguja in 2016 but a reduction in RDT-positivity rate 
can be observed not only in the study Shehias but on whole Unguja as well. 
 
Table 3. RDT testing and positivity rate at health facilities (HF) on Unguja and in the study Shehias. 
 
AREA 
 
TESTING RATE % (95% CI) 
 
POSITIVITY RATE % (95% CI) 
UNGUJA HF 
  
2014 26.8 (26.7-27.0) 1.7 (1.6-1-7) 
2015 25.6 (25.5-25.7) 2.0 (1.9-2.1) 
2016 30.4 (30.3-30.5) 1.2 (1.1-1.2) 
2017 (40 WEEKS) 31.7 (31.6-31.8) 1.4 (1.4-1.5) 
 
MDA/CONTROL HF 
  
2014 22.4 (22.1-22.7) 2.9 (2.7-3.2) 
2015 24.7 (24.4-25.1) 3.1 (2.8-3.4) 
2016 25.2 (24.8-25.6) 1.6 (1.4-1.8) 
2017 (40 WEEKS) 29.9 (29.4-30.3) 2.9 (2.7-3.3) 
Abbreviations: MDA, mass drug administration; HF, health facilities. 
 
MEEDS data from whole Unguja (visualized in figure 5) showed that there was generally 
lower malaria incidence on the whole island during the high transmission season 2016 
compared to other years. Figure 5 displays the weekly number of malaria cases reported to 
MEEDS by all health facilities on Unguja from week 1 2014 to week 40 2017. Figure 5 also 
displays the average weekly amount of rainfall (mm) of the six districts of Unguja. A 
reduction in rainfall during the main rains of the rainy season could be one reason behind the 
generally lower malaria incidence during the high transmission season of 2016 but no such 
reduction in rainfall could be visually observed; see figure 6. 
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Figure 5. Weekly reported clinical malaria cases (detected at health facilities) on the island Unguja (MEEDS data) 
in relation to rainfall data (average weekly rainfall (mm) of the six districts of Unguja). 
 
 
Figure 6. Total amount of rainfall (mm) of the six districts of Unguja during the 23 first weeks of 2015, 2016 and 
2017; thus including the main rainy season of each year. 
 
5 Discussion 
This report is and initial follow-up of a CRCT which aims to assess use of MDA as a malaria 
elimination strategy in Zanzibar. In April 2016, eight areas (Shehias) of relatively higher 
transmission (hotspots) were provided two rounds of DHAp + SLD Primaquine (0.25mg/kg) 
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MDA and cumulative malaria incidence was compared with eight similar control areas. The 
two rounds of MDA were conducted just before the onset of the annual malaria High 
transmission season occurring after the start of the rainy season. During the 16 months follow-
up period of this report (May 2016-Sep 2017) MDA fails to achieve a significantly lower 
cumulative incidence and risk of malaria in the MDA Shehias compared to control (RR=0.85; 
P=.10). No significant effect was either observed during the first 6 or 12 months of follow-up. 
There was no evidence in these preliminary investigations that MDA had had an impact on 
malaria transmission.   
The cumulative incidences of the study arms during high transmission season 2015 (the year 
before MDA) were analyzed to provide a baseline or pre-intervention comparison between 
MDA and control Shehias. Malaria incidence was slightly higher in the intervention arm at 
the baseline of the study, although the difference was not significant (RR = 1.23; 95% CI 
0.96-1.59; P=0.11). The high transmission season of 2016 starts directly after the 
administration of the first round of MDA (administered in the end of April 2016). The 
cumulative incidence was lower in both study arms during this period but still slightly higher 
in the intervention arm; RR=1.16 (95% CI 0.76-1.75; P=0.49). Not until the high transmission 
season of 2017, one year after MDA, a 32% lower risk of malaria can be observed in the 
MDA Shehias compared to control; RR=0.68 (95% CI 0.52-0.88; P=.004). The combined 
results imply that there is a transition from non-significantly higher to significantly lower 
malaria transmission in the MDA Shehias after MDA was conducted, if only high 
transmission season 2015, 2016 and 2017 are considered. This trend is also reflected in the 
cumulative incidence during the full 16 month follow-up, although the difference is still not 
significant in the end; RR=0.85 (95% CI 0.69-1.03; P=0.10). Furthermore, there was no 
evidence of an immediate short-term impact of MDA, neither when comparing the cumulative 
incidence during the first six nor 12 months; RR= 1.27 (95% CI 0.87-1.85; P=0.21) and RR= 
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1.17 (95% CI 0.86-1.61; P=0.32) respectively. This is visualized very well in the Kaplan-
Meier hazard plots of cumulative incidence of malaria seen in figure 2 A). In this figure, one 
can see that the cumulative incidence builds up fast in the control arm, but even faster in the 
intervention arm during the first time of the observation period and then levels out; this first 
slope represents the high transmission season 2016 (first 123 days), when the incidence of 
malaria is higher than during the rest of the year. Not until the onset of the high transmission 
season 2017 (last 123 days) the graphs (cumulative incidence) starts to once again accelerate 
upwards. Here it is easy to see that the cumulative incidence is higher in the control Shehias.  
To assess if MDA had an effect on local transmission all analyses were repeated after 
exclusion of all potentially imported cases. In general, the same trends apply for local 
transmission with the exception that a significant lower risk of clinical malaria can be seen 
during the full 16 months follow-up. During this period the risk of locally acquired malaria 
was 21% lower in MDA Shehias compared with control; RR=0.79 (95% CI 0.62-0.99; 
P=0.04). The Kaplan Meier hazard plot of local transmission in figure 2 B) clearly visualizes 
that no significant difference in local transmission was observed until the end of the study 
period during high transmission season 2017; RR=0.68 (95% CI 0.52-0.90 P=0.007). The 
weakness of excluding all potentially imported cases is that not all of them are actually 
imported. Many of the excluded cases could have acquired the infection through local 
transmission since the exclusion criteria – history of travel the last 30 days – does not specify 
if they traveled to a high-risk area of malaria. The imported cases are excluded with high 
sensitivity but very low specificity. 
Literature on the subject of MDA against malaria are united in their opinion that MDA gives 
and immediate effect on prevalence and incidence of malaria and that maintaining this effect 
is the issue (23, 27-29). The results of this report don’t support this conclusion, it rather 
suggests that the effect of MDA could be observed first in the long run. That is if the observed 
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significant lower risk of malaria towards the end of the study period (high transmission season 
2017) is in fact because of MDA. The analyses and results of this report are insufficient to 
determine if this is the case and further analyses are needed to determine the impact MDA had 
on malaria transmission. These analyses must take into consideration the study design of a 
CRCT. This report is only an initial investigation on the malaria transmission after MDA was 
conducted. 
If the reduction in risk towards the end of the study period actually is due to MDA, what 
would cause such a delay in observable effect? To display an effect, using the methodological 
aspects of this report, MDA fist had to equalize the potentially (non-significant) higher risk of 
malaria in the MDA Shehias that could be observed during high transmission season 2015 
(before MDA was administered) and during high transmission season 2016 (after MDA was 
administered). This report uses crude RRs to assess the effect of MDA and in theoretical 
numbers this equalization in risk would mean bringing an RR>1 down to RR=1. When the 
risk of malaria is equal in the study arms (RR=1), the intervention (MDA in this case) can 
start to display an effect. This is why more sophisticated analysis are needed, taking into 
consideration the study design of a CRCT and adjusting for baseline differences between the 
study arms.  
Another theory of why there is a delay in the effect of MDA, indicating a long-term effect, is 
that MDA may has been conducted too late in 2016. If the number of mosquitoes had started 
to rise earlier than expected (before MDA was administered) and they were already infected 
from biting humans carrying gametocytes, the mosquitos could still infect the same amount of 
people as in the control areas. MDA then depleted much of the sub-patient/asymptomatic 
gametocyte carriage in the MDA Shehias, meaning that not as big portion of the mosquitos of 
high transmission season 2017 became infected; therefore the effect of MDA could be 
observed first during the high transmission season one year after MDA. In theory this could 
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be the case but the prophylactic effect of the Piperaquine component of DHAp should have 
protected the population of the MDA Shehias during high transmission season 2016 from 
infection by already infected mosquitos. 
About 60% of the population of Zanzibar is rural and farming is the most common source of 
income (6). MDA was conducted at the beginning of the wet season when the population in 
theory should be more stationary due to increased farming capacity (25). To conduct MDA 
during this time of year therefore predisposes high community coverage since a greater part of 
the population is home. The coverage of the first round of MDA was: 91% received DHAp, 
87% received SLD Primaquine and 67% took the first dose as DOT. The coverage of the 
second round of MDA was: 88% received DHAp, 81% received SLD Primaquine and 48% 
took the first dose as DOT. A post MDA survey in a subset of the households of the MDA 
Shehias assessed the compliance to the full treatment to 84% and 96% in the first and second 
round respectively. According to these figures, the execution of the MDA study was highly 
successful and the high acceptance that these figures indicate can be a result of a well-
informed receiving end and a good delivery strategy. 
With high coverage and compliance achieved, why can’t a more pronounced effect be seen in 
the MDA Shehias compared to control. All study Shehias had similar coverage of vector 
control interventions at the baseline of the survey and no other malaria control activities (such 
as mass distribution of LLIN, mass IRS or other wide-scale interventions) were conducted in 
the study Shehias during the period of this report. The malaria incidence fell dramatically in 
both the intervention and control arms during high transmission season 2016 (immediately 
after MDA was conducted) compared to the high transmission season 2015 and 2017. Since 
the Shehias are small and in close proximity of each other, a dilution effect of MDA could 
have occurred, meaning that also the control Shehias benefited from the effect of MDA. This 
might be the case but the results of figure 5 shows that the transmission (incidence) was 
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generally lower on the whole island Unguja during the high transmission season of 2016 
compared to other years. If a dilution effect occurred, the effect of MDA generally lowered 
malaria transmission on whole Unguja which is not very probable. A more likely explanation 
is that there were a synergy of entomological and ecological factors contributing to the 
generally lower transmission observed on Unguja during high transmission season 2016. This 
reduction in incidence, occurring at the time when MDA was conducted, makes the results of 
this report hard to evaluate. The original study includes PCR measured malaria prevalence 
from both when MDA was conducted and three months after MDA. These results may 
provide valuable information about the effect the two rounds of MDA had on the 
asymptomatic/sub-patient parasite carriage in the MDA Shehias. 
There has been a renewed interest in MDA during the last couple of years due to emerging 
ACT resistance and the difficulties in targeting the asymptomatic/sub-patient parasite 
reservoir thought to maintain 20-50% of remaining transmission in low transmission settings. 
MDA is one of the few methods available today to target these individuals. To determine the 
impact of MDA, high quality CRCT are needed; few studies of this kind have been conducted 
(27). In 1999 the first CRCT assessing the effect of MDA against malaria was conducted in 
an area of high transmission in the Gambia (35). In this study, a single round of MDA with 
artesunate and a single dose of sulfadoxine-pyrimethamine fails to reduce the malaria 
incidence among children and the prevalence among adults compared to control during 20 
weeks of follow-up. This drug combination does not affect mature gametocytes and this in 
combination with the study taking place in a high transmission setting are possible reasons for 
a not detectable effect.       
This report highlights the difficulties of conducting a CRCT in a low transmission setting 
where transmission is unpredictable. Unpredictable variations in transmission and prevalence 
has been observed in other regions where MDA were tested. A MDA CRCT from Tanzania 
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could not evaluate the effect of MDA since the transmission had almost completely 
disappeared from the area prior the administration of MDA (36). 
In 2015, another CRCT using two rounds of DHAp MDA was conducted in Zambia (37). The 
short-term impact of MDA was evaluated 5 months after the intervention and a non-
significant 70% lower cumulative infection incidence could be observed in the areas receiving 
MDA compared with control (crude incidence rate ratio = 0.30 (95% CI 0.06–1.49; P = .14)). 
A reduction in PCR measured parasite prevalence of 87% (adjusted odds ratio = 0.13 (95% CI 
0.02–0.92; P = .04) compared with control was achieved. This study also suffered from lower 
incidence than expected in the control arm. As a result, the statistical power to detect 
significant differences were reduced. 
The three studies discussed above all reached a coverage >80%. Despite that the effect of 
MDA is not entirely certain. MDA is recommended in the Greater Mekong subregion to 
contain artemisinin resistant strains and prohibit the spread to other regions. A pilot study 
from this area was recently published (38). It used three rounds of MDA with DHAp + SLD 
primaquine and the MDA intervention was implemented together with distribution of LLIN 
and rapid diagnosis and treatment via a “malaria post”. The control areas also received LLIN 
distribution and the rapid diagnosis and treatment intervention which led to big reductions in 
malaria prevalence (PCR) in the control areas. The study design therefore makes it hard to 
conclude the impact of MDA alone; they report 88% prevalence reduction in MDA villages 
and 85% prevalence reduction in control villages. In addition, being a pilot, the study 
provides low power to detect the effect of MDA.  
6 Conclusions and implications 
There is no evidence in these preliminary investigations that two rounds of MDA had an 
effect on malaria transmission in the eight hotspot Shehias on Zanzibar. However, this report 
provides insufficient information to fully determine the impact MDA had. Further analyses 
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are needed to fully understand the transmission observed after MDA was conducted. These 
analyses should adjust for variations between the study arms at baseline and take into 
consideration the study design of a CRCT. The results of this report consist of descriptive 
statistics and represents only an initial investigation/evaluation of the malaria transmission 
using crude risk ratios. During the high transmission season 2016 there were an unexpected 
reduction in malaria incidence on the whole island where this study took place. Since most of 
the yearly malaria cases occur during this period, this reduction in incidence makes it hard to 
evaluate the effect of MDA since there were few cases in both the intervention and control 
arm respectively. Previous studies have concluded that the effect of MDA on malaria 
transmission is rapid and the difficulty is to maintain this effect. No such direct effect could 
be observed in this report. The significantly lower risk of malaria observed in the intervention 
arm during the high transmission season 2017, one year after MDA was administered, cannot 
be attributed to the effect of MDA based on these preliminary findings. 
However, MDA may still play a vital role in Zanzibar’s and other malaria elimination areas’ 
efforts to combat malaria, and the results of this report at this stage can’t be used to neither 
recommend nor discard the use of MDA as a malaria elimination strategy.  
7 Populärvetenskaplig sammanfattning 
Massmedicinering mot malaria på Zanzibar 
Malaria är trots att det är en botbar och förebyggbar sjukdom en stor börda i många delar av 
världen; särskilt i regionerna av Afrika som ligger söder om Sahara. Att utrota malaria anses 
möjligt och massmedicinering av malariamedicin är en av metoderna som kan spela en stor 
roll för att lyckas. Detta projekt utvärderar massmedicinering för att uppnå utrotning av 
malaria på Zanzibar, en ögrupp utanför Tanzania. Massmedicinering innebär att alla i ett 
område får botande doser läkemedel oavsett om dem är sjuka eller inte. Denna metod 
övervägs eftersom många bär malariaparasiter utan att få symptom på sjukdom och kan därför 
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ovetande sprida sjukdomen vidare. Massmedicinering innebär att man inte behöver identifiera 
dessa symptomfria bärare, vilket är svårt med de verktyg som idag används för att ställa 
diagnosen malaria. 
I april 2016 delades det ut två omgångar massmedicinering mot malaria i åtta områden på 
Zanzibar. Antalet nya fall av malaria i dessa områden jämfördes med antalet fall i åtta 
liknande områden som inte fick någon massmedicinering. Mycket är okänt om 
massmedicinering mot malaria varför studier som denna är viktiga. 
Denna rapport är en uppföljning på studien som genomfördes förra året på Zanzibar. 
Resultaten i denna rapport visar inga antydningar på att massmedicinering har haft en effekt 
på antalet nya malariafall som uppstod under de 16 månader som följde massmedicineringen. 
Tidigare studier har visat att massmedicinering ger en snabb effekt på förekomsten av malaria 
och att problemet är att underhålla dessa resultat i det långa loppet. Resultaten i denna rapport 
visar på en minskad risk av malaria först ett år efter massmedicineringen genomfördes, denna 
effekt tros därför inte vara på grund av massmedicinering utan på grund av andra orsaker. För 
att fullt utvärdera effekten som massmedicineringen på Zanzibar hade måste ytterligare och 
mer avancerade analyser genomföras än vad som ligger till grund för resultatet i denna 
rapport. Massmedicinering kan fortfarande vara ett kraftfullt verktyg på vägen mot att utrota 
malaria. 
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